Early endostatin treatment inhibits colorectal cancer cell spread to the liver
Author Information
Author(s): te Velde E A, Reijerkerk A, Brandsma D, Vogten J M, Wu Y, Kranenburg O, Voest E E, Gebbink M, Borel Rinkes I H M
Primary Institution: University Medical Center Utrecht
Hypothesis
Can early administration of recombinant human endostatin reduce the spread of colorectal cancer cells to the liver?
Conclusion
Early treatment with endostatin significantly reduces the number of colorectal cancer cells that spread to the liver.
Supporting Evidence
- Endostatin treatment started 2 hours before tumor cell injection resulted in the lowest tumor load.
- Endostatin reduced the percentage of injected tumor cells in the liver to 34.4% compared to 57.4% in controls at 15 minutes.
- Endostatin pretreatment led to a two-fold decrease in tumor cell adhesion to endothelial cells under flow conditions.
Takeaway
Giving a medicine called endostatin before cancer cells can spread to the liver helps stop them from sticking there.
Methodology
Mice were treated with endostatin at different time points before and after tumor cell injection, and the effects on tumor cell seeding and growth were measured.
Limitations
The study was conducted in mice, which may not fully replicate human responses.
Participant Demographics
Balb/C male mice, aged 10 weeks.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website